Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical and Molecular Allergy
Published in: Clinical and Molecular Allergy 1/2020

Open Access 01-12-2020 | Multiple Sclerosis | Case Report

Fingolimod-associated macular edema controlled with nepafenac non-steroidal anti-inflammatory opthalmologic applications

Authors: Rachel Husmann, John B. Davies, Malik Ghannam, Brent Berry, Praful Kelkar

Published in: Clinical and Molecular Allergy | Issue 1/2020

Login to get access

Abstract

Background

Fingolimod, an immunomodulatory agent, is used for the treatment of relapsing–remitting multiple sclerosis (RRMS). Fingolimod-associated macular edema (FAME) is a known complication with an incidence of 0.4%. The current recommendation for treatment of FAME is cessation of fingolimod. There are few case reports with management of FAME with steroid eye drops.

Case presentation

A 38-year-old Caucasian female patient with history of relapsing–remitting multiple sclerosis (RRMS) and treated with fingolimod developed Fingolimod-associated macular edema (FAME). Nevertheless, FAME was successfully treated with nonsteroidal anti-inflammatory eye drops without discontinuation of fingolimod.

Conclusion

FAME may be managed with non-steroidal eye drops without discontinuation of fingolimod in appropriate patient monitored with close follow up.
Literature
1.
Jain N, Bhatti MT. Fingolimod-associated macular edema: incidence, detection, and management. Neurology. 2012;78:672–80.CrossRef
2.
Zarbin MA, Jampol LM, Jager RD, et al. Ophthalmic evaluations in clinical studies of fingolimod (FTY720) in multiple sclerosis. Ophthalmology. 2013;120(7):1432–9.CrossRef
3.
Tedesco-Silva H, et al. Randomized controlled trial of FTY720 versus MMF in de novo renal transplantation. Transplantation. 2006;82(12):1689–97.CrossRef
4.
Cohen JA, Chun J. Mechanisms of fingolimod’s efficacy and adverse effects in multiple sclerosis. Ann Neurol. 2011;69(5):759–77.CrossRef
5.
Thoo S, Cugati S, Lee A, Chen C. Successful treatment of fingolimod-associated macular edema with intravitreal triamcinolone with continued fingolimod use. Mult Scler J. 2015;21:249–51.CrossRef
6.
Minuk A, Belliveau MJ, Almeida DR, Dorrepaal SJ, Gale JS. Fingolimod-associated macular edema: resolution by sub-tenon injection of triamcinolone with continued fingolimod use. JAMA Ophthalmol. 2013;131:802–4.CrossRef
7.
Chui J, Herkes GK, Chang A. Management of fingolimod-associated macular edema. JAMA Ophthalmol. 2013;131:694–6.CrossRef
8.
Afshar AR, Fernandes JK, Patel RD, Ksiazek SM, Sheth VS, Reder AT, Hariprasad SM. Cystoid macular edema associated with fingolimod use for multiple sclerosis. JAMA Ophthalmol. 2013;131:103–7.CrossRef
9.
Li V, Kane J, Chan HH, Hall AJ, Butzkueven H. Continuing fingolimod after development of macular edema: a case report. Neurol Neuroimmunol Neuroinflamm. 2014;1:1–2.CrossRef
10.
Nevanac (nepafenac) [prescribing information]. Fort Worth, TX: Alcon Laboratories, Inc; January 2019.
11.
Nevanac (nepafenac) [product monograph]. Dorval, Quebec, Canada; Novartis Pharmaceuticals Canada; January 2018.
Metadata
Title
Fingolimod-associated macular edema controlled with nepafenac non-steroidal anti-inflammatory opthalmologic applications
Authors
Rachel Husmann
John B. Davies
Malik Ghannam
Brent Berry
Praful Kelkar
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Clinical and Molecular Allergy / Issue 1/2020
Electronic ISSN: 1476-7961
DOI
https://doi.org/10.1186/s12948-020-00119-4

Other articles of this Issue 1/2020

Clinical and Molecular Allergy 1/2020 Go to the issue

Review

Allergic reactions to genus Morus plants: a review

Research

Physicians’ prescribing behaviour and clinical practice patterns for allergic rhinitis management in Italy

Review

Urticaria: recommendations from the Italian Society of Allergology, Asthma and Clinical Immunology and the Italian Society of Allergological, Occupational and Environmental Dermatology

Review

Oral health in asthmatic patients: a review

Review

New perspectives in allergen specific immunotherapy driven by big trials with house dust mite sublingual SQ® tablets

Review

Management of the patient with allergic and immunological disorders in the pandemic COVID-19 era